SHELTON, Conn. , Jan. 31, 2014 -- Cara Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price ... (more)
via Shelton Newswire http://ift.tt/1bGJ6tI
via Shelton Newswire http://ift.tt/1bGJ6tI
No comments:
Post a Comment